Preconditioning Against Myocardial Infarction—Its Features and Adenosine-Mediated Mechanism

  • Tetsuji Miura
Part of the Medical Intelligence Unit book series (MIU.LANDES)


Myocardial infarction is the leading cause of mortality and morbidity in industrialized countries. Prognosis of the patients is determined primarily by the extent of infarct in the heart (i.e., infarct size).1 Because of this fact, for more than 20 years basic and clinical investigators have devoted much effort to limiting myocardial infarct size. There have been two approaches to this objective: early reperfusion and enhancement of myocardial resistance to ischemia. Several methodologies have been developed over a decade to recanalize the occluded coronary artery and it has been established that reperfusion improves hemodynamics, decreases infarct size, and improves prognosis.2 In contrast, attempts to enhance myocardial resistance against infarction by pharmacological agents3–7 has achieved only limited success in animal experiments. However, in 1986 Murry and co-workers8 found that exposing the myocardium to brief ischemia markedly limits the infarct size due to the subsequent 40 minutes of coronary occlusion in canine hearts. This cardioprotective effect, termed “preconditioning,” was not accompanied by alterations of coronary collateral flow, indicating that myocardial resistance to infarction was directly enhanced. In order to understand this novel form of cardioprotection against infarction, we undertook a series of studies to clarify the features and mechanisms of preconditioning.


Infarct Size Adenosine Receptor Ischemic Precondition Rabbit Heart Myocardial Infarct Size 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    van der Laarse AA, van Leeuwen FT, Krul R et al. The size of infarction as judged enzymatically in 1974 patients with acute myocardial infarction. Relation with symptomatology, infarct localization and type of infarction. Int J Cardiol 1988; 19: 191–207.PubMedCrossRefGoogle Scholar
  2. 2.
    Topol EJ. Thrombolytic intervention. In: Topol EJ, ed. Textbook of interventional cardiology. 2nd ed. Philadelphia: WB Saunders Company, 1994: 68–111.Google Scholar
  3. 3.
    Reimer KA, Rasmussen MM, Jennings RB. Reduction by propranolol of myocardial necrosis following temporary coronary artery occlusion in dogs. Circ Res 1973; 33: 353–363.PubMedCrossRefGoogle Scholar
  4. 4.
    Hearse DJ, Yellon DM, Downey JM. Can beta blockers limit myocardial infarct size? Eur Heart J 1986; 7: 925–930.PubMedGoogle Scholar
  5. 5.
    Kloner RA, Braunwald E. Effects of calcium antagonists on infarcting myocardium. Am J Cardiol 1987; 59: 84B - 94B.PubMedCrossRefGoogle Scholar
  6. 6.
    Adachi T, Miura T, Noto T et al. Does verapamil limit myocardial infarct size in a heart deficient in xanthine oxidase? Clin Exp Pharmacol Physiol 1990; 17: 769–779.PubMedCrossRefGoogle Scholar
  7. 7.
    Downey JM, Yellon DM. Do free radicals contribute to myocardial cell death during ischemia-reperfusion? In: Yellon DM, Jennings RB, eds. Myocardial protection:the pathophysiology of reperfusion and reperfusion injury. New York: Raven Press, 1992: 35–57.Google Scholar
  8. 8.
    Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay in lethal injury in ischemic myocardium. Circulation 1986; 74: 1124–1136.PubMedCrossRefGoogle Scholar
  9. 9.
    Miura T, Yellon DM, Hearse DJ et al. Determinants of infarct size during permanent occlusion of a coronary artery in the closed chest dog. J Am Coll Cardiol 1987; 9: 647–654.PubMedCrossRefGoogle Scholar
  10. 10.
    Miura T, Downey JM, Ooiwa H et al. Progression of myocardial infarction in a collateral flow deficient species. Jpn Heart J 1989; 30: 695–708.PubMedCrossRefGoogle Scholar
  11. 11.
    Miura T, Adachi T, Ogawa T et al. Myocardial infarct size-limiting effect of ischemic preconditioning: Its natural decay and the effect of repetitive preconditioning. Cardiovasc Pathol 1992; 1: 147–154.CrossRefGoogle Scholar
  12. 12.
    Miura T, Goto M, Miki T et al. Glibenclamide, a blocker of ATP-sensitive potassium channels, abolishes infarct size-limitation by preconditioning in rabbits anesthetised with xylazine/pentobarbital, but not with pentobarbital alone. J Cardiovasc Pharmacol 1995; 25: 531–538.PubMedCrossRefGoogle Scholar
  13. 13.
    Yamasaki K, Tanaka M, Yokota R et al. Preconditioning with 15 min ischemia extends myocardial infarct size after subsequent 30 min ischemia in rabbits. J Mol Cell Cardiol 1994; 26:CCXIV (Abstract).Google Scholar
  14. 14.
    Miura T, Goto M, Urabe K et al. Does myocardial stunning contribute to infarct size limitation by ischemic preconditioning? Circulation 1991; 84: 2504–2512.PubMedCrossRefGoogle Scholar
  15. 15.
    Li CG, Vasquez JA, Gallagher KP et al. Myocardial protection with preconditioning. Circulation 1990; 82: 609–619.PubMedCrossRefGoogle Scholar
  16. 16.
    Murry CE, Richard VJ, Jennings RB et al. Myocardial protection is lost before contractile function recovers from ischemic preconditioning. Am J Physiol 1991; 260: H796 - H804.PubMedGoogle Scholar
  17. 17.
    Schwartz ER, Mohri M, Sacck S et al. Duration of infarct size limiting effect of ischemic preconditioning in the pig. Circulation 1991; 84 (suppl II): II - 432 (Abstract).CrossRefGoogle Scholar
  18. 18.
    Schaper W, Ito BR. The energetics of “stunned” myocardium. In: de Jong JW, ed. Myocardial Energy Metabolism. Dordrecht: Martinus Nijhoff Publishing 1988: 203–213.CrossRefGoogle Scholar
  19. 19.
    Dean EN, Schlafer M, Nicklas JM. The oxygen consumption paradox of “stunned myocardium” in dogs. Basic Res Cardiol 1990; 85: 120–131.PubMedCrossRefGoogle Scholar
  20. 20.
    Laster SB, Becker LC, Ambrosio G et al. Reduced aerobic metabolic efficiency in globally “stunned” myocardium. J Mol Cell Cardiol 1989; 21: 419–426.PubMedCrossRefGoogle Scholar
  21. 21.
    Ohgoshi Y, Goto Y, Futaki S et al. Increased oxygen cost of contractility in stunned myocardium of dog. Circ Res 1991; 69: 975–988.PubMedCrossRefGoogle Scholar
  22. 22.
    Murry CE, Richard VJ, Reimer KA et al. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 1990; 66: 913–931.PubMedCrossRefGoogle Scholar
  23. 23.
    Kida M, Fujiwara H, Ishida M et al. Ischemic preconditioning preserves creatine phosphate and intracellular pH. Circulation 1991; 84: 2495–2503.PubMedCrossRefGoogle Scholar
  24. 24.
    Goto M, Miura T, Itoya M et al. Reduction of regional contractile function by preconditioning ischemia does not play a permissive role in the infarct size-limitation by the preconditioning. Basic Res Cardiol 1993; 88: 594–606.PubMedCrossRefGoogle Scholar
  25. 25.
    Matsuda M, Catena TG, Vander Heide RS et al. Cardiac protection by ischaemic preconditioning is not mediated by myocardial stunning. Cardiovasc Res 1993; 27: 585–592.PubMedCrossRefGoogle Scholar
  26. 26.
    Liu GS, Thornton J, Van Winkle D et al. Protection against infarction afforded by preconditioning is mediated by AI receptors in rabbit heart. Circulation 1991; 84: 350–356.PubMedCrossRefGoogle Scholar
  27. 27.
    Yellon DM, Maxwell MP, Hearse DJ et al. Infarct size limitation—real or artifactual. Studies with flurbiprofen using a reperfusion model. In: Dhalla NS, Hearse DJ eds. Advances in myocardiology. London: Plenum Press, 1985: 619–627.Google Scholar
  28. 28.
    Shirato C, Miura T, Ooiwa H et al. Tetrazolium artefactually indicates superoxide dismutase-induced salvage in reperfused rabbit heart. J Mol Cell Cardiol 1989; 21: 1187–1193.PubMedCrossRefGoogle Scholar
  29. 29.
    Tsuchida A, Miura T, Miki T et al. Role of adenosine receptor activation in infarct size limitation by preconditioning in the heart. Cardiovasc Res 1992; 26: 456–461.PubMedCrossRefGoogle Scholar
  30. 30.
    Grover GJ, Sleph PG, Dzwonczyk S. Role of ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine Al-receptors. Circulation 1992; 86: 1310–1316.PubMedCrossRefGoogle Scholar
  31. 31.
    Yao Z, Gross GJ. A comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs. Comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs. Efficacy, time-course, and role of KATP channels. Circulation 1994; 89: 1229–1236.PubMedCrossRefGoogle Scholar
  32. 32.
    Van Winkle DM, Chien GL, Wolff RA et al. Cardioprotection provided by adenosine receptor activation is abolished by blockade of the KATP channel. Am J Physiol 1994; 266: H829 - H839.PubMedGoogle Scholar
  33. 33.
    Li Y, Kloner RA. The cardioprotective effects of ischemic preconditioning are not mediated by adenosine receptors in rat hearts. Circulation 1993; 87: 1642–1648.PubMedCrossRefGoogle Scholar
  34. 34.
    Liu Y, Downey JM. Ischemic preconditioning protects rat heart against infarction. Am J Physiol 1993; 263: H1107 - H1112.Google Scholar
  35. 35.
    Thornton JD, Liu GS, Olsson RA et al. Intravenous pretreatment with Al-selective adenosine analogs protects the heart against infarction. Circulation 1992; 85: 659–665.PubMedCrossRefGoogle Scholar
  36. 36.
    Miura T, Ogawa T, Iwamoto T et al. Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning. Circulation 1992; 86: 979–985.PubMedCrossRefGoogle Scholar
  37. 37.
    Numazawa K, Sakuma I, Kobayashi T et al. Dipyridamole protects canine heart against ischemia/reperfusion by raising cardiac interstitial adenosine via inhibition of its deamination as well as reuptake. Circulation 1993: (suppl I); I-431 (Abstract).Google Scholar
  38. 38.
    Alano T, Ochiai Y, Hidaka H. Selective inhibition of separated forms of human platelet cyclic nucleotide phosphodiesterase by platelet aggregation inhibitors. Mol Pharmacol 1977; 13: 400–406.Google Scholar
  39. 39.
    Blass KE, Block HU, Forster W et al. Dipyridamole: a potent stimulator of prostacyclin (PGI2) biosynthesis. Br J Pharmacol 1980; 68: 71–73.PubMedCrossRefGoogle Scholar
  40. 40.
    Itoya M, Miura T, Sakamoto J et al. Nucleoside transport inhibitors enhance the infarct size-limiting effect of ischemic preconditioning. J Cardiovasc Pharmacol 1994; 24: 846–852.PubMedCrossRefGoogle Scholar
  41. 41.
    Tsuchida A, Liu GS, Mullane K et al. Acadesine lowers temporal threshold for the myocardial infarct size-limiting effect of preconditioning. Cardiovasc Res 1993; 27: 116–120.PubMedCrossRefGoogle Scholar
  42. 42.
    Miki T, Miura T, Sakamoto J et al. Does preconditioning (PC) require myocardial adenosine level elevation during both PC ischemic and subsequent ischemic insult? J Mol Cell Cardiol 1994; 26: CCXVI (Abstract).Google Scholar
  43. 43.
    Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev 1990; 70: 761–845.PubMedGoogle Scholar
  44. 44.
    Lloyd HGE, Schrader J. Adenosine metabolism in the guinea pig heart: the role of cytosolic S-adenosyl-L-homocysteine hydrolase, 5’-nucleotidase and adenosine kinase. Eur Heart J 1993; 14 (Suppl I): 27–33.PubMedGoogle Scholar
  45. 45.
    Headrick JP, Matherne G, Berne RM. Myocardial adenosine formation during hypoxia: effects of ecto-5’-nucleotidase inhibition. J Mol Cell Cardiol 1992; 24: 295–303.PubMedCrossRefGoogle Scholar
  46. 46.
    Raatikainen MJP, Peuhkurinen KJ, Hassinen IE. Contribution of endothelium and cardiomyocytes to hypoxia-induced adenosine release. J Mol Cell Cardiol 1994; 26: 1069–1080.PubMedCrossRefGoogle Scholar
  47. 47.
    Chaudry IH. Does ATP cross the cell plasma membrane? Yale J Biol Med 1982; 55: 1–10.PubMedGoogle Scholar
  48. 48.
    Johnson RG. Accumulation of biological amines into chromaffin granules: A model for hormone and neurotransmitter transport. Physiol Rev 1988; 68: 232–307.Google Scholar
  49. 49.
    Fredholm EB, Hedqvist P, Lindstrom K et al. Release of nucleosides and nucleotides from the rabbit heart by sympathetic nerve stimulation. Acta Physiol Scand 1982; 116: 285–295.PubMedCrossRefGoogle Scholar
  50. 50.
    Kitakaze M, Hori M, Takashima S et al. Ischemic preconditioning increases adenosine release and 5’-nucleotidase activity during myocardial ischemic and reperfusion in dogs: implication for myocardial salvage. Circulation 1993; 87: 208–215.PubMedCrossRefGoogle Scholar
  51. 51.
    Kitakaze M, Hori M, Morioka T et al. Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5’-nucleotidase activity and attenuation of adenosine release. Circulation 1994; 89: 1237–1246.PubMedCrossRefGoogle Scholar
  52. 52.
    Van Wylen DGL. Effect of ischemic preconditioning on intersitial purine metabolite and lactate accumulation during myocardial ischemia. Circulation 1994; 89: 2283–2289.PubMedCrossRefGoogle Scholar
  53. 53.
    Miki T, Miura T, Suzuki K et al. Does ectosolic 5’-nucleotidase contribute to preconditioning in the rabbit heart? Circulation 1994; 90 (suppl I): I - 477 (Abstract).Google Scholar
  54. 54.
    Kirsch GE, Codiana J, Birnbaumer L et al. Coupling of ATP-sensitive K channels to A, receptors by G1 proteins in rat ventricular myocytes. Am J Physiol 1990; 259: H820 - H826.PubMedGoogle Scholar
  55. 55.
    Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992; 70: 223–233.PubMedCrossRefGoogle Scholar
  56. 56.
    Auchampach JA, Gross GJ. Adenosine A, receptors, KATP channels, and ischemic preconditioning in dogs. Am J Physiol 1993; 264: H1327 - H1336.PubMedGoogle Scholar
  57. 57.
    Schultz R, Rose J, Heusch G. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine. Am J Physiol 1994; 267: H1341 - H1352.Google Scholar
  58. 58.
    Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischemic preconditioning is reversible with glibenclamide. Cardiovasc Res 1993; 27: 617–622.PubMedCrossRefGoogle Scholar
  59. 59.
    Thornton JD, Thornton CS, Sterling DL et al. Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts. Circ Res 1993; 72: 44–49.PubMedCrossRefGoogle Scholar
  60. 60.
    Wyatt JD, Scott AW, Richardson ME. The effects of prolonged ketaminexylazine intravenous infusion on arterial blood pH, blood gases, mean arterial blood pressure, heart and respiratory rates, rectal temperature and reflexes in the rabbit. Lab Anim Sci 1989; 39: 411–416.PubMedGoogle Scholar
  61. 61.
    Sylviana TJ, Bergman NG, Fox JG. Effects of yohimbine on bradycardia and duration of recumbency in ketamine/xylazine anesthetized ferrets. Lab Anim Sci 1990; 40: 178–182.Google Scholar
  62. 62.
    Jennings RB, Murry CE, Reimer KA. Energy metabolism in preconditioning and control myocardium; effect of total ischemia. J Mol Cell Cardiol 1991; 23: 1449–1458.PubMedCrossRefGoogle Scholar
  63. 63.
    Sleph PG, Grover GJ. Protective effects of cromakalim and BMS-180448 in ischemic rat hearts treated with potassium cardioplegia. J Mol Cell Cardiol 1994; 26:CLXVII (Abstract).Google Scholar
  64. 64.
    Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischaemic rabbit heart by protein kinase C activation. Am J Physiol. 1994; 266: H1145 - H1152.PubMedGoogle Scholar
  65. 65.
    Sakamoto J, Miura T, Goto M et al. Limitation of myocardial infarct size by adenosine Ai-receptor activation is abolished by protein kinase C inhibitors in the rabbit. Cardiovasc Res 1995; 29: 682–688.PubMedGoogle Scholar
  66. 66.
    Ward CA, Moffat MP. Positive and negative inotropic effects of phorbol 12-myristate 13-acetate: relationship to PKC-dependence and changes in [Ca2i. J Mol Cell Cardiol 1992; 24: 937–948.PubMedCrossRefGoogle Scholar
  67. 67.
    Kohl C, Linck B, Schmitz W et al. Effects of carbachol and R(-)-N6phenylisopropyladenosine on myocardial inositol phosphate content and force of contraction. Br J Pharmacol 1990; 101: 829–34.PubMedCrossRefGoogle Scholar
  68. 68.
    Przyklenk K, Sussman MA, Kloner RA. Fluorescence microscopy reveals no evidence of protein kinase C activation in preconditioned canine myocardium. Circulation 1994; 90 (suppl. I): I - 647 (Abstract).Google Scholar
  69. 69.
    Vogt A, Barancik M, Weihrauch D et al. Protein kinase C inhibitors reduce infarct size in pig heart in vivo. Circulation 1994; 90 (suppl. I): I - 647 (Abstract).Google Scholar
  70. 70.
    Black SC, Fagbemi SO, Chi L et al. Phorbol ester-induced ventricular fibrillation in the Langendorff-perfused rabbit heart: antagonism by staurosporine and glibenclamide. J Mol Cell Cardiol 1993; 25: 1427–38.PubMedCrossRefGoogle Scholar
  71. 71.
    Hara H, Onodera H, Yoshidomi M et al. Staurosporine, a novel protein kinase C inhibitor, prevents postischemic neuronal damage in the gerbil and rat. J Cereb Blood Flow Metab 1990; 10: 646–53.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Tetsuji Miura

There are no affiliations available

Personalised recommendations